GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Barinthus Biotherapeutics PLC (NAS:BRNS) » Definitions » Accumulated Depreciation

BRNS (Barinthus Biotherapeutics) Accumulated Depreciation : $0.00 Mil (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Barinthus Biotherapeutics Accumulated Depreciation?

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Barinthus Biotherapeutics's annual accumulated depreciation increased from Dec. 2021 ($-0.89 Mil) to Dec. 2022 ($-1.32 Mil) and increased from Dec. 2022 ($-1.32 Mil) to Dec. 2023 ($-3.69 Mil).


Barinthus Biotherapeutics Accumulated Depreciation Historical Data

The historical data trend for Barinthus Biotherapeutics's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Barinthus Biotherapeutics Accumulated Depreciation Chart

Barinthus Biotherapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Accumulated Depreciation
-0.25 -0.48 -0.89 -1.32 -3.69

Barinthus Biotherapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Accumulated Depreciation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -3.69 - - -

Barinthus Biotherapeutics Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.


Barinthus Biotherapeutics Accumulated Depreciation Related Terms

Thank you for viewing the detailed overview of Barinthus Biotherapeutics's Accumulated Depreciation provided by GuruFocus.com. Please click on the following links to see related term pages.


Barinthus Biotherapeutics Business Description

Traded in Other Exchanges
N/A
Address
Unit 6-10, Rutherford Avenue, Zeus Building, Harwell, GBR, OX11 0DF
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer.
Executives
Joseph Scheeren director THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Robin Wright director THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
William Enright director, officer: Chief Executive Officer 910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG MD 20878
Nadege Pelletier officer: Chief Scientific Officer C/O VACCITECH PLC, UNIT 6-10, ZEUS BUILDING RUTHERFORD AVENUE, HARWELL, DIDCOT X0 OX11 0DF
Gemma Brown officer: Chief Financial Officer VACCITECH PLC, UNIT 6-10, ZEUS BUILDING, RUTHERFORD AVENUE, HARWELL, DIDCOT X0 OX11 0DF
Graham Griffiths officer: Chief Business Officer THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Christopher Ellis officer: Chief Operating Officer THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Anne M. Phillips director C/O TREVENA, INC., 1018 WEST 8TH AVENUE, KING OF PRUSSIA PA 19406
Oxford Science Enterprises Plc 10 percent owner 46 WOODSTOCK ROAD, OXFORD X0 OX2 6HT
Karen A Dawes director 579 BELLEVUE AVE, NEWPORT RI 02840
Pierre A. Morgon director THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Margaret Marshall officer: Chief Medical Officer THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Thomas George Evans officer: Chief Scientific Officer THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Alex Hammacher director THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Georgy Egorov officer: Chief Financial Officer THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE

Barinthus Biotherapeutics Headlines

From GuruFocus

Vaccitech to Present at Upcoming November Investors Conferences

By Value_Insider Value_Insider 11-09-2022